Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Lancet HIV. 2022 Sep 7;9(10):e680–e689. doi: 10.1016/S2352-3018(22)00195-3

Table 3.

Distribution of PrEP adherence outcomes in HPTN 082 cohort over follow-up1

Week 13 (N=380) Week 26 (N=373) Week 52 (N=369) p-value2
TFV-DP ≥ 700 fmol/punch3 91/370 (25%) 76/364 (21%) 30/347 (9%) <0.0001
TFV ≥ 40 ng/mL4 183/379 (48%) 142/372 (38%) 63/361 (18%) <0.0001
Quantifiable TFV-DP concentration3 309/370 (84%) 205/364 (56%) 109/347 (31%) <0.0001
Quantifiable TFV concentration4 245/379 (65%) 173/372 (47%) 92/361 (26%) <0.0001

ARV=antiretroviral medication; STI=sexually transmitted infection; TFV-DP=tenofovir diphosphate; TFV=tenofovir

1

Data are presented as median (interquartile range) for continuous variables and frequency (percentage) for categorical variables

2

p-value for trend based on regression model assessing whether frequencies significantly differed by visit

3

Denominantors are shown in each column to reflect the total number of DBS samples that were tested for TFV-DP concentration at each visit

4

Denominantors are shown in each column to reflect the total number of plasma samples that were tested for TFV concentration at each visit